TD Cowen Has Lowered Expectations for Surgery Partners (NASDAQ:SGRY) Stock Price

Surgery Partners (NASDAQ:SGRY) had its target price dropped by equities researchers at TD Cowen from $28.00 to $20.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price would suggest a potential upside of 49.70% from the company’s previous close.

A number of other research analysts also recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a research note on Wednesday. UBS Group lowered their target price on Surgery Partners from $29.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday. Barclays reduced their price target on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday. Mizuho decreased their price objective on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Surgery Partners in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Surgery Partners presently has a consensus rating of “Moderate Buy” and an average price target of $24.45.

Surgery Partners Price Performance

Shares of NASDAQ SGRY opened at $13.36 on Thursday. The company has a market capitalization of $1.73 billion, a PE ratio of -21.55 and a beta of 1.95. The company has a quick ratio of 1.72, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The stock’s 50 day moving average price is $15.20 and its 200-day moving average price is $18.15. Surgery Partners has a twelve month low of $12.25 and a twelve month high of $24.64.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The business had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.44 earnings per share. On average, equities analysts anticipate that Surgery Partners will post 0.67 EPS for the current year.

Surgery Partners announced that its Board of Directors has initiated a stock buyback plan on Thursday, February 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 9.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC raised its stake in Surgery Partners by 104.2% in the 4th quarter. Hsbc Holdings PLC now owns 1,931,577 shares of the company’s stock valued at $30,151,000 after acquiring an additional 985,748 shares during the period. Alpine Global Management LLC purchased a new stake in Surgery Partners during the fourth quarter valued at about $175,000. Empowered Funds LLC boosted its position in Surgery Partners by 1,340.9% during the fourth quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock worth $2,494,000 after purchasing an additional 150,216 shares during the period. One68 Global Capital LLC bought a new position in Surgery Partners during the fourth quarter worth about $371,000. Finally, Man Group plc purchased a new position in shares of Surgery Partners in the fourth quarter worth about $5,080,000.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Several analysts maintained buy/outperform ratings despite lowering targets, signaling continued conviction in recovery potential. Analyst Expectations For Surgery Partners’s Future
• Positive Sentiment: TD Cowen cut its price target to $20 but kept a “buy” rating, implying substantial upside from current levels if company execution improves. TD Cowen lowers PT to $20, keeps Buy
• Positive Sentiment: UBS trimmed its target to $21 while retaining a “buy” stance, another signal that analysts still see medium‑term upside despite near‑term weakness. UBS lowers PT to $21, keeps Buy
• Neutral Sentiment: Some commentary frames the current slump as a potential buying opportunity for long‑term investors, but emphasizes execution and margin recovery are key. Has Surgery Partners Slump Opened A New Opportunity For Investors?
• Negative Sentiment: Barclays cut its price target sharply to $14, signaling more conservative near‑term expectations and adding downward pressure on the stock. Barclays Lowers Surgery Partners Price Target to $14
• Negative Sentiment: Q4 results: revenue modestly beat, but EPS missed expectations and management flagged margin pressure — the core reason for the selloff and heightened execution risk. SGRY Q4 2025 Earnings Call Highlights
• Negative Sentiment: Shares hit a new 52‑week low after the earnings miss and analyst downgrades, reflecting elevated near‑term downside and investor concern about margin recovery. Surgery Partners Sets New 52-Week Low on Disappointing Earnings

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.